Recent clinical trials have targeted alternative mechanisms/pathways,4 including interleukin 1 (IL-1) pathway inhibition to ameliorate patients’ inflammatory response, either via anti-IL-1β antibodies (Canakinumab; IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH)5) or IL-1R antagonists (IL-1Ra) (Anakinra; (AlcHepNet)6). This evidence concerns the gene IL1B and alcoholic hepatitis.